- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper studies auxiliary gene supervision scaling in spatial gene expression prediction from H&E images. The authors show that expanding supervised gene panels through multi-task learning does not always improve target gene prediction and may introduce negative transfer. They formulate gene-supervision scaling by gradually increasing auxiliary supervision while keeping target genes fixed, and propose VAST (Verified Asymmetric Supervision Transfer), which uses a protect–propose–verify mechanism to preserve a target-only predictor, learn auxiliary-induced corrections, and selectively apply transfers based on training-slide evidence. Experiments on 15 HEST-1k and STimage datasets demonstrate improved target gene PCC and reduced negative transfer. Overall, the paper identifies an important problem and proposes an interpretable transfer control framework; however, its novelty beyond existing multi-task transfer control methods and the reliability of the verification mechanism require further validation.
Critical strengths
1.This paper does not simply assume that “more gene supervision is always better”, but systematically analyzes the impact of gene-supervision scaling on fixed target genes. The authors show that expanding the supervision panel may improve average performance while also degrading some target genes. This is a practically meaningful observation.
2.Compared with conventional multi-task learning where all tasks directly update shared parameters, VAST restricts auxiliary information through a rejectable transfer interface using a target-only anchor, auxiliary proposal, and evidence-based verification.
Critical weaknesses
1.The methodological novelty of this work is limited and highly related to existing negative transfer control methods in multi-task learning. The core idea of VAST is to preserve a target task model, use auxiliary tasks to generate residual corrections, and use a gate to decide whether to accept the transfer. This idea has strong similarities with existing multi-task learning approaches such as task weighting, gradient surgery, and mixture-of-experts gating. Although the paper applies this idea to the spatial transcriptomics gene supervision scaling scenario, it does not sufficiently clarify the fundamental difference between VAST and existing negative transfer control methods.
2.VAST uses training-only slide-level evidence to estimate the transfer weight α. However, the relationship between this evidence and final test-time generalization performance has not been sufficiently demonstrated.
3.The paper compares with methods such as STNet and BLEEP, but lacks more direct transfer control baselines, such as GradNorm, PCGrad, uncertainty weighting, and learned residual adapters. These methods also aim to address multi-task negative transfer. Without these comparisons, the source of VAST’s advantages remains unclear.
4.VAST assumes that useful information exists in the expanded gene panel and mainly focuses on “how to safely transfer” auxiliary supervision. However, in practical applications, a key question is: which auxiliary genes are worth including? Although the paper discusses gene-supervision scaling, it does not deeply investigate the effects of auxiliary gene quality, gene correlation, and biological pathway relevance on VAST.
5.The authors emphasize that verification does not use validation/test labels, but the evidence is obtained from outer-training slides. For small-scale spatial transcriptomics datasets, the number of training samples is often limited and slide-level variance can be large. Therefore, the stability of training-only estimation requires further analysis.
Questions for authors
1.What is the fundamental difference between VAST and existing negative transfer control methods in multi-task learning, such as gradient surgery, task weighting, and mixture-of-experts gating? Does the main novelty come from the PPV framework or its application to spatial transcriptomics?
2.How can the authors demonstrate that training-only verification evidence can reliably predict transfer quality during testing? Could the authors provide a correlation analysis between α and the actual gene-level transfer gain?
3.Could the authors include more direct multi-task negative transfer baselines, such as PCGrad, GradNorm, uncertainty weighting, and Mixture-of-Experts?
4.How does VAST handle low-quality or irrelevant auxiliary genes? Can it automatically identify biologically irrelevant auxiliary supervision?